About this trial
The molecular mechanisms underlying developmental programming of childhood obesity remain poorly understood. Here, the investigators address major questions about early childhood obesity programming by studying CD3+ T-cells from intrauterine growth restricted (IUGR) newborns who have an increased risk for obesity and other metabolic disorders in adult life.
Eligibility criteria
Qualifiers
Healthy singleton term intrauterine growth restricted (IUGR) and appropriate for gestational age (AGA) infants whose mothers are followed by the Obstetric Department of Montefiore Medical Center and who deliver at the Weiler Division of Montefiore Medical Center. Infants will be classified as IUGR if birth weight is <10th percentile for gestational age and gender based on World Health Organization (WHO) growth curves. Infants will be classified as AGA if birth weight percentile is >10th and <90th percentile
Reproductive age women, healthy enough to achieve pregnancy
Deliver a single healthy live term infant at ≥37 weeks' gestational age (GA)
All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
Disqualifiers
Multiple gestation
Maternal depression
Maternal renal disease
History of maternal smoking in the 2nd and 3rd trimester of pregnancy
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Montefiore Medical Center
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Icahn School of Medicine at Mount Sinai
Collaborator
Hackensack Meridian Health Center for Discovery and Innovation
Collaborator
University of California, San Francisco
Collaborator
University of Wisconsin, Madison
Collaborator
Gencove
Collaborator